These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Free-breathing high-spatial-resolution delayed contrast-enhanced three-dimensional viability MR imaging of the myocardium at 3.0 T: a feasibility study.
    Author: Amano Y, Matsumura Y, Kumita S.
    Journal: J Magn Reson Imaging; 2008 Dec; 28(6):1361-7. PubMed ID: 19025943.
    Abstract:
    PURPOSE: To assess the feasibility of free-breathing high-spatial-resolution delayed contrast-enhanced three-dimensional (3D) viability magnetic resonance imaging (MRI) at 3.0 T for the detection of myocardial damages. MATERIALS AND METHODS: Twenty-five patients with myocardial diseases, including myocardial infarction and cardiomyopathies, were enrolled after informed consent was given. Free-breathing 3D viability MRI with high spatial resolution (1.5 x 1.25 x 2.5 mm) at 3.0 T, for which cardiac and navigator gating techniques were employed, was compared with breath-hold two-dimensional (2D) viability imaging (1.77 x 1.18 x 10 mm) for assessment of contrast-to-noise ratio (CNR) and myocardial damage. RESULTS: Free-breathing 3D viability imaging was achieved successfully in 21 of the 25 patients. This imaging technique depicted 84.6% of hyperenhancing myocardium with a higher CNR between hyperenhancing myocardium and blood and with excellent agreement for the transmural extension of myocardial damage (k = 0.91). In particular, the 3D viability images delineated the myocardial infarction and linear hyperenhancing myocardium, comparable to the 2D viability images. CONCLUSION: Free-breathing high-spatial-resolution delayed contrast-enhanced 3D viability MRI using 3.0 T was feasible for the evaluation of hyperenhancing myocardium, as seen with myocardial infarction and cardiomyopathies.
    [Abstract] [Full Text] [Related] [New Search]